1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cardiovascular Drug-Eluting Stents(DES) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Cardiovascular Drug-Eluting Stents(DES) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Cardiovascular Drug-Eluting Stents(DES) by Country/Region, 2018, 2022 & 2029
2.2 Cardiovascular Drug-Eluting Stents(DES) Segment by Type
2.2.1 Passive Coating
2.2.2 Active Coating
2.3 Cardiovascular Drug-Eluting Stents(DES) Sales by Type
2.3.1 Global Cardiovascular Drug-Eluting Stents(DES) Sales Market Share by Type (2018-2023)
2.3.2 Global Cardiovascular Drug-Eluting Stents(DES) Revenue and Market Share by Type (2018-2023)
2.3.3 Global Cardiovascular Drug-Eluting Stents(DES) Sale Price by Type (2018-2023)
2.4 Cardiovascular Drug-Eluting Stents(DES) Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Cardiovascular Drug-Eluting Stents(DES) Sales by Application
2.5.1 Global Cardiovascular Drug-Eluting Stents(DES) Sale Market Share by Application (2018-2023)
2.5.2 Global Cardiovascular Drug-Eluting Stents(DES) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Cardiovascular Drug-Eluting Stents(DES) Sale Price by Application (2018-2023)
3 Global Cardiovascular Drug-Eluting Stents(DES) by Company
3.1 Global Cardiovascular Drug-Eluting Stents(DES) Breakdown Data by Company
3.1.1 Global Cardiovascular Drug-Eluting Stents(DES) Annual Sales by Company (2018-2023)
3.1.2 Global Cardiovascular Drug-Eluting Stents(DES) Sales Market Share by Company (2018-2023)
3.2 Global Cardiovascular Drug-Eluting Stents(DES) Annual Revenue by Company (2018-2023)
3.2.1 Global Cardiovascular Drug-Eluting Stents(DES) Revenue by Company (2018-2023)
3.2.2 Global Cardiovascular Drug-Eluting Stents(DES) Revenue Market Share by Company (2018-2023)
3.3 Global Cardiovascular Drug-Eluting Stents(DES) Sale Price by Company
3.4 Key Manufacturers Cardiovascular Drug-Eluting Stents(DES) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cardiovascular Drug-Eluting Stents(DES) Product Location Distribution
3.4.2 Players Cardiovascular Drug-Eluting Stents(DES) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cardiovascular Drug-Eluting Stents(DES) by Geographic Region
4.1 World Historic Cardiovascular Drug-Eluting Stents(DES) Market Size by Geographic Region (2018-2023)
4.1.1 Global Cardiovascular Drug-Eluting Stents(DES) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Cardiovascular Drug-Eluting Stents(DES) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Cardiovascular Drug-Eluting Stents(DES) Market Size by Country/Region (2018-2023)
4.2.1 Global Cardiovascular Drug-Eluting Stents(DES) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Cardiovascular Drug-Eluting Stents(DES) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Cardiovascular Drug-Eluting Stents(DES) Sales Growth
4.4 APAC Cardiovascular Drug-Eluting Stents(DES) Sales Growth
4.5 Europe Cardiovascular Drug-Eluting Stents(DES) Sales Growth
4.6 Middle East & Africa Cardiovascular Drug-Eluting Stents(DES) Sales Growth
5 Americas
5.1 Americas Cardiovascular Drug-Eluting Stents(DES) Sales by Country
5.1.1 Americas Cardiovascular Drug-Eluting Stents(DES) Sales by Country (2018-2023)
5.1.2 Americas Cardiovascular Drug-Eluting Stents(DES) Revenue by Country (2018-2023)
5.2 Americas Cardiovascular Drug-Eluting Stents(DES) Sales by Type
5.3 Americas Cardiovascular Drug-Eluting Stents(DES) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cardiovascular Drug-Eluting Stents(DES) Sales by Region
6.1.1 APAC Cardiovascular Drug-Eluting Stents(DES) Sales by Region (2018-2023)
6.1.2 APAC Cardiovascular Drug-Eluting Stents(DES) Revenue by Region (2018-2023)
6.2 APAC Cardiovascular Drug-Eluting Stents(DES) Sales by Type
6.3 APAC Cardiovascular Drug-Eluting Stents(DES) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cardiovascular Drug-Eluting Stents(DES) by Country
7.1.1 Europe Cardiovascular Drug-Eluting Stents(DES) Sales by Country (2018-2023)
7.1.2 Europe Cardiovascular Drug-Eluting Stents(DES) Revenue by Country (2018-2023)
7.2 Europe Cardiovascular Drug-Eluting Stents(DES) Sales by Type
7.3 Europe Cardiovascular Drug-Eluting Stents(DES) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cardiovascular Drug-Eluting Stents(DES) by Country
8.1.1 Middle East & Africa Cardiovascular Drug-Eluting Stents(DES) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Cardiovascular Drug-Eluting Stents(DES) Revenue by Country (2018-2023)
8.2 Middle East & Africa Cardiovascular Drug-Eluting Stents(DES) Sales by Type
8.3 Middle East & Africa Cardiovascular Drug-Eluting Stents(DES) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cardiovascular Drug-Eluting Stents(DES)
10.3 Manufacturing Process Analysis of Cardiovascular Drug-Eluting Stents(DES)
10.4 Industry Chain Structure of Cardiovascular Drug-Eluting Stents(DES)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cardiovascular Drug-Eluting Stents(DES) Distributors
11.3 Cardiovascular Drug-Eluting Stents(DES) Customer
12 World Forecast Review for Cardiovascular Drug-Eluting Stents(DES) by Geographic Region
12.1 Global Cardiovascular Drug-Eluting Stents(DES) Market Size Forecast by Region
12.1.1 Global Cardiovascular Drug-Eluting Stents(DES) Forecast by Region (2024-2029)
12.1.2 Global Cardiovascular Drug-Eluting Stents(DES) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cardiovascular Drug-Eluting Stents(DES) Forecast by Type
12.7 Global Cardiovascular Drug-Eluting Stents(DES) Forecast by Application
13 Key Players Analysis
13.1 MIV Therapeutics
13.1.1 MIV Therapeutics Company Information
13.1.2 MIV Therapeutics Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.1.3 MIV Therapeutics Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 MIV Therapeutics Main Business Overview
13.1.5 MIV Therapeutics Latest Developments
13.2 Orbusneich
13.2.1 Orbusneich Company Information
13.2.2 Orbusneich Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.2.3 Orbusneich Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Orbusneich Main Business Overview
13.2.5 Orbusneich Latest Developments
13.3 Promed Medical
13.3.1 Promed Medical Company Information
13.3.2 Promed Medical Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.3.3 Promed Medical Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Promed Medical Main Business Overview
13.3.5 Promed Medical Latest Developments
13.4 Relisys Medical
13.4.1 Relisys Medical Company Information
13.4.2 Relisys Medical Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.4.3 Relisys Medical Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Relisys Medical Main Business Overview
13.4.5 Relisys Medical Latest Developments
13.5 Reva Medical
13.5.1 Reva Medical Company Information
13.5.2 Reva Medical Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.5.3 Reva Medical Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Reva Medical Main Business Overview
13.5.5 Reva Medical Latest Developments
13.6 Sahajanand
13.6.1 Sahajanand Company Information
13.6.2 Sahajanand Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.6.3 Sahajanand Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Sahajanand Main Business Overview
13.6.5 Sahajanand Latest Developments
13.7 Sino Medical
13.7.1 Sino Medical Company Information
13.7.2 Sino Medical Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.7.3 Sino Medical Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sino Medical Main Business Overview
13.7.5 Sino Medical Latest Developments
13.8 Sorin
13.8.1 Sorin Company Information
13.8.2 Sorin Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.8.3 Sorin Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sorin Main Business Overview
13.8.5 Sorin Latest Developments
13.9 Terumo Medical
13.9.1 Terumo Medical Company Information
13.9.2 Terumo Medical Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.9.3 Terumo Medical Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Terumo Medical Main Business Overview
13.9.5 Terumo Medical Latest Developments
13.10 Abbott Vascular
13.10.1 Abbott Vascular Company Information
13.10.2 Abbott Vascular Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.10.3 Abbott Vascular Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Abbott Vascular Main Business Overview
13.10.5 Abbott Vascular Latest Developments
13.11 Advantec Vascular
13.11.1 Advantec Vascular Company Information
13.11.2 Advantec Vascular Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.11.3 Advantec Vascular Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Advantec Vascular Main Business Overview
13.11.5 Advantec Vascular Latest Developments
13.12 B.Braun Melsengen AG
13.12.1 B.Braun Melsengen AG Company Information
13.12.2 B.Braun Melsengen AG Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.12.3 B.Braun Melsengen AG Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 B.Braun Melsengen AG Main Business Overview
13.12.5 B.Braun Melsengen AG Latest Developments
13.13 Biosensors
13.13.1 Biosensors Company Information
13.13.2 Biosensors Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.13.3 Biosensors Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Biosensors Main Business Overview
13.13.5 Biosensors Latest Developments
13.14 Boston Scientific
13.14.1 Boston Scientific Company Information
13.14.2 Boston Scientific Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.14.3 Boston Scientific Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Boston Scientific Main Business Overview
13.14.5 Boston Scientific Latest Developments
13.15 MicroPort Medical
13.15.1 MicroPort Medical Company Information
13.15.2 MicroPort Medical Cardiovascular Drug-Eluting Stents(DES) Product Portfolios and Specifications
13.15.3 MicroPort Medical Cardiovascular Drug-Eluting Stents(DES) Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 MicroPort Medical Main Business Overview
13.15.5 MicroPort Medical Latest Developments
14 Research Findings and Conclusion
※参考情報 心血管薬剤溶出ステント(DES)は、冠動脈疾患の治療において重要な役割を果たす医療機器です。これらのステントは、心臓の冠動脈に挿入され、血管が狭くなったり閉塞するのを防ぐために使用されます。DESは患者の治療において大きな革新をもたらした技術の一つであり、従来の金属製ステントに比べて再狭窄のリスクを大幅に減少させることができます。 DESの定義は、デバイスの一部として、抗悪性腫瘍薬などの薬剤をコーティングしたステントであることです。この薬剤は、血管内の異常な細胞の成長を抑制し、再狭窄(血管が再び狭くなる現象)を防ぐ役割を果たします。2000年代初頭に初めて市販されたDESは、急速に医療現場での標準治療となりました。 DESの特徴としては、まず第一に、薬剤の効果により再狭窄率を低下させる点が挙げられます。従来のバルーン拡張法や金属製のステントでは、おおよそ25%から30%程度の再狭窄率が見込まれたのに対し、DESは5%から15%にまで低下します。これにより、再度の治療を要する可能性が大幅に減少します。 次に、DESは通常、バイオ適合性の高いマテリアルで製造されており、血管内での長期的な安定性も確保しています。加えて、DESに使用される薬剤は、特定の細胞増殖を抑制することが求められ、これによって内皮細胞の迅速な再生を促進するように設計されています。これにより、血栓形成のリスクも最小限に抑えられます。 DESの種類には、さまざまな形式がありますが、主に使用される薬剤の種類によって分類することができます。例えば、シロリウムとパクリタキセルを含むステントが代表的です。これらの薬剤は、異なるメカニズムで細胞の増殖を抑制し、各々の患者に応じた最適な選択が可能です。 用途としては、主に狭心症や心筋梗塞の治療に用いられます。これらの疾患は、冠動脈の狭窄によって引き起こされ、血液の流れが不足することで心筋にダメージを与えます。DESを用いることで、血流を改善し、臓器への酸素供給を確保することができます。また、急性冠症候群(ACS)や高リスク患者においても、DESは非常に効果的です。 関連技術として、心血管診断のための画像技術も重要です。主に冠動脈造影(Angiography)やCTスキャン、MRIなどが挙げられ、これらの技術を用いることで病変の評価やステント挿入の適正を判断します。また、最近の技術革新として、バイオ吸収性ステントも注目されています。これらは、体内で時間とともに分解されるため、長期間の物理的な存在が不要な場合に適しています。これにより、患者の生理的な条件に応じたより適切な治療が可能になります。 心血管薬剤溶出ステントは、臨床研究においても多くのデータが集積されており、その安全性と有効性は広く認識されていますが、すべての患者に対して最適な選択肢というわけではありません。特に、出血リスクや抗血小板療法を要する患者においては、慎重な判断が必要です。使用後も定期的なフォローアップが求められ、患者の状況に応じた適切な管理が重要です。 結論として、心血管薬剤溶出ステントは、冠動脈疾患の治療において革新的な進歩をもたらしている医療機器と言えます。患者への負担を軽減し、より効果的な治療を提供するための技術として、今後もさらなる研究と発展が期待されます。医療現場での多面的なアプローチが求められる中、DESはその一助となるでしょう。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/